A Study Of Galcanezumab In Participants With Episodic Cluster Headache

Episodic Cluster Headache Clinical Trial

Official title:
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study of LY2951742 in Patients With Episodic Cluster Headache

Status Completed

Clinical Trial Summary

The main purpose of this study is to evaluate the efficacy and safety of the study drug known as Galcanezumab in participants with episodic cluster headaches.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02397473
Study type	Interventional
Source	Eli Lilly and Company
Contact
Status	Completed
Phase	Phase 3
Start date	May 22, 2015
Completion date	June 4, 2018

View Details

See also
Status	Clinical Trial	Phase
Not yet recruiting	`NCT01341548` - Civamide Nasal Solution for Cluster Headache	Phase 3
Terminated	`NCT02209155` - R-Verapamil for the Prophylaxis of Episodic Cluster Headache	Phase 2
Unknown status	`NCT00399243` - Sumatriptan 4 mg Statdose in the Acute Treatment of Cluster Headache	Phase 4
Completed	`NCT02797951` - A Study of LY2951742 (Galcanezumab) in Participants With Cluster Headache	Phase 3
Completed	`NCT00033839` - A Phase III Study of Civamide Nasal Solution (Zucapsaicin) for the Treatment of Episodic Cluster Headache	Phase 3
Terminated	`NCT02945046` - A Study to Evaluate the Efficacy and Safety of TEV-48125 (Fremanezumab) for the Prevention of Episodic Cluster Headache (ECH)	Phase 3
Completed	`NCT00069082` - Intranasal Civamide for Episodic Cluster Headache	Phase 3